

Biomarkers

Part 1: Technologies & Applications

By

Prof. K.K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

April 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor+ 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

April 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	26
1. Introduction	28
Definitions	28
Historical aspects of biomarkers.....	28
Classification of biomarkers.....	29
Biomarker as a response to therapeutic intervention	30
Pharmacokinetic/pharmacodynamics biomarkers	30
Predictive biomarkers	30
Valid biomarkers.....	31
Types of biomarkers	32
Genes as biomarkers.....	32
<i>Silent gene mutations.....</i>	<i>32</i>
Epigenetic biomarkers	32
Exosomes as biomarkers	33
Proteins as biomarkers	33
<i>Proteomics.....</i>	<i>34</i>
DNA biomarkers	34
Mitochondrial DNA	34
<i>Mitochondrial mutations.....</i>	<i>34</i>
RNA biomarkers.....	35
<i>Transcriptomics</i>	<i>35</i>
<i>MicroRNAs</i>	<i>36</i>
Metabolomics	36
Glycomics	37
Single nucleotide polymorphisms	37
<i>Haplotyping.....</i>	<i>38</i>
Cell biomarkers of disease	38
Stem cell biomarkers.....	38
<i>Association of stem cell biomarkers with disease.....</i>	<i>39</i>
<i>Cancer stem cell biomarkers.....</i>	<i>39</i>
<i>Endoglin as a functional biomarker of stem cells</i>	<i>39</i>
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	<i>39</i>
<i>Protein expression profile as biomarker of stem cells.....</i>	<i>40</i>
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	<i>40</i>
<i>SSEA-4 as biomarker of MSCs</i>	<i>40</i>
Gaseous mediators as biomarkers of disease.....	40
Autoantibodies as biomarkers of autoimmune diseases.....	41
Comparison of various types of biomarkers	41
Biomarkers and systems biology	42
Systems biology approach to biomarker identification.....	43
Relation of biomarkers to other technologies and healthcare	43
Biomarkers and translational medicine.....	44
Role of biomarkers in monitoring of diseases	45
Limitations of use of biomarkers in healthcare	45
2. Technologies for Discovery of Biomarkers	46
Introduction	46
The ideal biomarker	46
Genomic technologies.....	46
Gene expression	46
<i>Whole genome expression array</i>	<i>47</i>
<i>Gene expression profiling on whole blood samples</i>	<i>48</i>
<i>Profiling gene expression patterns of white blood cells.....</i>	<i>48</i>
Tissue microarrays for study of biomarkers	48
Technologies for detection of miRNAs as biomarkers	49
Microarrays for analysis of miRNA gene expression	49
<i>Microarrays vs quantitative PCR for measuring miRNAs.....</i>	<i>50</i>
Point-of-care detection of circulating miRNAs as biomarkers.....	50
Epigenomic technologies	50
Discovery of methylation biomarkers.....	51
Proteomic technologies	52
2D GE	53
ProteoCarta® integrated proteomics discovery platform	53
Isotope-coded affinity tags.....	54
Liquid chromatography-MS/MS	54
Lucid Proteomics System	55
Magnetics beads for protein biomarker discovery	55

MASStermind™	55
Combined analysis of protein and nucleic-acid biomarkers	56
Mass spectrometry	56
2D PAGE and mass spectrometry	57
Imaging mass spectrometry	57
MALDI mass spectrometry for biomarker discovery	58
Quantitative tandem MS	58
Single-molecule mass spectrometry using a nanopore	59
Requirements for MS-based proteomic biomarker development	59
Nucleic Acid Programmable Protein Array	59
Protein tomography	60
Protein biochips/microarrays and biomarkers	60
Antibody array/affinity proteomics-based biomarker discovery	60
Detection of biomarkers using peptide array technology	62
ProtoArray®	62
Protein nanobiochip	62
Gene expression microarray data as a source of protein biomarkers	63
Quantification of protein biomarkers	63
CyTOF for quantification of biomarkers	63
Digital protein biomarker measurement	64
Multiple reaction monitoring assays	64
Real-time PCR for quantification of protein biomarkers	64
Search for biomarkers in body fluids	65
Challenges and strategies for discovery of protein biomarkers in plasma	65
Technologies for removal of highly abundant proteins in blood	65
3D structure of CD38 as a biomarker	66
BD™ Free Flow Electrophoresis System	67
Isotope tags for relative and absolute quantification	67
Plasma protein microparticles as biomarkers	67
Proteome partitioning	68
Stable isotope tagging methods	68
Technology to measure both the identity and size of the biomarker	69
Selected reaction monitoring MS	69
Targeted MS for verification of biomarkers	70
Biomarkers in the urinary proteome	71
Peptides as biomarkers of disease	71
Analysis of peptides in bodily fluids	71
Antibody biomarker discovery via evolution of peptides	72
Selected reaction monitoring for validating peptide biomarkers	73
Serum peptidome patterns	73
StSCAPA method for quantitating proteins and peptides in plasma	73
Comparison of proteomic profiling technologies for discovery of biomarkers	74
Verification for interlaboratory reproducibility of protein biomarkers	74
Significance of similar protein biomarkers in different tissues	74
Glycomic technologies	75
Cellular glycomics for discovery of cellular biomarkers	76
Metabolomic technologies	76
Genome-wide association studies for identification of metabolic biomarkers	77
Genetic influences on human blood metabolites	77
Lipid profiling	77
Mass spectrometry for discovery of metabolic biomarkers in plasma	78
Role of metabolomics in biomarker identification and pattern recognition	78
Urinary profiling by capillary electrophoresis	78
Validation of biomarkers in large-scale human metabolomics studies	79
Lipidomics	79
Disease biomarkers in breath	80
Portable breath test for volatile organic compounds	80
Detection of breath biomarkers by sensation technology	80
Detection of breath biomarkers by nanosensors	81
Detection of breath biomarkers optical frequency comb spectroscopy	81
Detection of breath biomarkers by infrared absorption spectroscopy	81
Detection of biomarkers by electronic nose	81
Fluorescent indicators for biomarkers	82
Molecular imaging technologies	82
Computer tomography	82
Magnetic resonance imaging	83
Positron emission tomography	83
Advantages of imaging biomarkers	83
Monitoring in vivo gene expression by molecular imaging	84
Molecular imaging in vivo as a biomarker	84
Challenges and future of molecular imaging	85

<i>Basic research in molecular imaging</i>	85
<i>Imaging intracellular NADH as a biomarker of disease</i>	85
<i>Devices for molecular imaging</i>	86
<i>Imaging biomarkers in clinical trials</i>	86
<i>Molecular imaging in clinical practice</i>	86
Nuclear magnetic resonance	86
Chemical derivatization to enhance biomarker detection by NMR	87
Fluxomics by using NMR	87
Nanobiotechnology	87
Dip Pen Nanolithography	88
Nanomaterials for biolabeling	88
<i>Quantum dot molecular labels</i>	89
<i>Bioconjugated QDs for multiplexed profiling of biomarkers</i>	90
<i>Magnetic nanotags for multiply detection of biomarkers</i>	90
Nanoparticles for molecular imaging	90
Nanoparticles for discovering biomarkers	91
Nanoproteomics and biomarkers	91
<i>High-field asymmetric waveform ion mobility mass spectrometry</i>	91
Nanosensors for measuring biomarkers in blood	92
Nanobiochip sensor technique for analysis of oral cancer biomarkers	92
Future prospects of application of nanobiotechnology for biomarkers	92
Bioinformatics	93
Biomarker Workflow Guide	93
Analysis of microarray data for selecting useful biomarkers	93
Role of bioinformatics in discovery of protein biomarkers	93
Role of bioinformatics in detection of cancer biomarkers	94
Biomarker databases	94
Gene networks as biomarkers	95
Role of bioinformatics in integrating various data and biomarker discovery	95
Evaluation of biomarker studies	96
3. Biomarkers and Molecular Diagnostics	98
Introduction	98
Molecular diagnostic technologies	98
Polymerase chain reaction	98
<i>Amplification</i>	98
<i>Target selection</i>	99
<i>Detection of amplified DNA</i>	99
<i>Limitations of PCR</i>	99
Real-time PCR systems	100
<i>Limitations of real-time PCR</i>	100
<i>Future applications of real-time qPCR</i>	101
<i>Real-time qPCR for quantification of circulating mtDNA</i>	101
Combined PCR-ELISA	101
Non-PCR methods	102
<i>Linked Linear Amplification</i>	102
Transcription mediated amplification	102
Rapid analysis of gene expression	102
WAVE nucleic acid fragment analysis system	103
DNA probes with conjugated minor groove binder	103
Rolling circle amplification technology	104
<i>Gene-based diagnostics through RCAT</i>	104
<i>RCAT-immunodiagnosics</i>	105
<i>RCAT-biochips</i>	105
<i>RCAT-pharmacogenomics</i>	105
Circle-to-circle amplification	105
Biomarkers and high throughput molecular screening	106
Detection and expression profiling of miRNA	106
Real-time PCR for expression profiling of miRNAs	106
Use of LNA to explore miRNA	107
Microarrays for analysis of miRNA gene expression	107
Devices for biomarkers	107
Biochips and microarrays	107
<i>Applications of biochips/microarrays</i>	108
<i>Role of biochip/microarrays in discovery of biomarkers</i>	108
Biosensors for biomarkers	109
<i>Biosensor for analysis of sweat biomarkers</i>	109
4. Biomarkers for Drug Discovery & Development	112
Introduction	112
Biomarker technologies for drug discovery	112

Proteomics-based biomarkers for drug discovery	112
Chemoproteomics	113
<i>Activity-based chemical proteomics</i>	113
Transcriptomics for drug discovery	113
Metabolomics for drug discovery	114
Biomarkers and drug safety	114
Biomarkers of adverse drug reactions	114
Applications of biomarkers in drug safety studies	115
Genomic technologies for toxicology biomarkers	115
Proteomic technologies for toxicology biomarkers	116
Metabonomic technologies for toxicology biomarkers	116
Integration of genomic and metabonomic data to develop toxicity biomarkers	116
Toxicology studies based on biomarkers	117
<i>Biomarker of genotoxicity</i>	118
<i>Biomarkers of hepatotoxicity</i>	118
<i>Biomarkers of nephrotoxicity</i>	119
<i>Cardiotoxicity</i>	121
<i>Neurotoxicity</i>	121
Applications of biomarkers for drug development	122
Application of metabolomics/metabolomics for drug development	122
Application of biomarkers by the pharmaceutical companies	123
Biomarkers in clinical trials	124
<i>NIH recommendations on the use of biomarkers in clinical trials</i>	124
<i>Advantages of biomarkers for drug development</i>	126
<i>Limitations and problems with use of biomarkers in clinical trials</i>	126
Development of static and dynamic biomarkers	127
Molecular imaging as a biomarker in drug development	127
<i>Molecular imaging in preclinical studies</i>	127
<i>Molecular imaging in clinical trials</i>	128
<i>Prospects of molecular imaging in drug discovery and development</i>	129
Pharmacogenomic biomarker information in drug labels	129
Role of biomarkers in vaccine development	130
Role of biomarkers in relation to stage of drug discovery and development	130
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development	131
Role of biomarkers for drug development in cardiovascular disorders	132
Role of biomarkers for drug development in neurological disorders	132
Significance of biomarkers in drug development	132
Organizations & resources for biomarker-based drug development	133
Biomarker Alliance	133
Biomarkers Consortium	133
Molecular Libraries and Imaging Roadmap of NIH	134
Rare Diseases Clinical Research Consortia	135
Future of biomarker-based drug development	135
5. Role of Biomarkers in Healthcare	138
Introduction	138
Biomarkers of inflammation	139
ESR and CRP as biomarkers of inflammation	139
Metabolic biomarkers of inflammation	140
YKL-40 as a biomarker inflammation and predictor of mortality	140
Biomarkers of allergic disorders	140
Biomarkers of oxidative stress	141
1,4-dihydroxynonane-mercapturic acid	141
Oxidized phospholipids	141
Oxidative DNA damage	142
Proteins as biomarkers of oxidative stress in diseases	142
Testing for oxidative stress	142
Biomarkers of hypoxia	143
Pathophysiology of hypoxia	143
Hypoxia inducible factor as biomarker of hypoxia and response to oxygenation	143
Identification of hypoxia biomarkers from exhaled breath	143
Metabolic biomarkers of hypoxia	144
Biomarkers of liver disease	144
Breath biomarkers of liver disease	144
Biomarkers of liver injury	144
Fibrosis and cirrhosis of liver	145
FibroMax	145
Hepatic encephalopathy	145
miRNA biomarkers of liver disease	146
Viral hepatitis B and C	146
<i>Biomarkers of hepatitis C</i>	146

<i>Biomarkers of hepatitis B</i>	147
Biomarkers of pancreatitis	147
Biomarkers of renal disease	148
Biomarkers of lupus nephritis	148
Biomarkers of diabetic nephropathy	149
Cystatin C as biomarker of glomerular filtration rate (GFR)	149
Estimated GFR and albuminuria as biomarkers of chronic kidney disease	149
Proteomic biomarkers of acute kidney injury	150
Symmetric dimethylarginine as biomarker of chronic kidney disease in dogs	150
Troponin-T as a biomarker for predicting end-stage renal disease	150
Biomarkers in pediatrics	150
Pediatric critical care	150
Biomarkers of acute kidney injury in children	151
Biomarkers of miscellaneous disorders	151
Biomarkers of carbon monoxide poisoning	151
Biomarkers of Castleman disease	151
Biomarkers of erectile dysfunction	152
Biomarkers of fever	152
Biomarkers of heat stroke	153
Biomarkers of hyponatremia	153
Biomarkers of inflammatory bowel disease	153
Biomarkers of radiation injury	154
Biomarkers for prediction of all-cause mortality	155
Biomarkers common to multiple diseases	155
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy	156
Biomarkers of gene-environmental interactions in human disease	156
Application of biomarkers in animal health	157
6. Biomarkers in Metabolic Disorders	160
Biomarkers of acute intermittent porphyria	160
Liver X receptors	160
Biomarkers of diabetes mellitus	160
<i>β-cell function as biomarker of diabetes</i>	162
<i>Biomarkers of hyperglycemia</i>	162
<i>Biomarkers of diabetes-associated oxidative stress</i>	162
<i>Biomarkers of inflammation associated with diabetes</i>	162
<i>Biomarkers of renal complications in diabetes mellitus type 2</i>	163
<i>Biomarkers of diabetes</i>	163
<i>Biomarkers of prediabetes</i>	163
<i>Biomarkers of insulin resistance</i>	163
<i>Glycosylated hemoglobin in diabetes mellitus</i>	164
<i>Glycated albumin as a biomarker of diabetes mellitus</i>	164
<i>Low C-peptide as a biomarker of complications of diabetes type 1</i>	164
<i>Personalized management of diabetes mellitus based on biomarkers</i>	165
Biomarkers of metabolic syndrome	165
<i>Adiponectin</i>	165
<i>Cystatin C</i>	166
<i>Human plasma lipidome</i>	166
<i>Neurotensin as biomarker of obesity</i>	167
7. Biomarkers in Immune Disorders	170
Introduction	170
Biomarkers relevant to organ transplantation	170
Biomarkers of graft versus host disease	170
Biomarkers of renal allograft failure	171
Biomarkers of renal transplant tolerance	172
Biomarkers of lung transplant rejection	173
Biomarkers of GVHD following transplantation of hematopoietic cells	173
Plasma biomarkers of response to therapy of GVHD	173
Systemic lupus erythematosus	174
Adiponectin as biomarker of SLE	174
Current management and need for biomarkers of SLE	174
Role of collaborative efforts and databases of SLE biomarkers	175
C4d-bearing reticulocytes	175
CB-CAPS	175
Epigenetic biomarkers of SLE	175
Genetic loci of SLE	176
HMGB1	176
Biomarkers of systemic sclerosis	176
Biomarkers of Sjögren syndrome	177

8. Biomarkers of Musculoskeletal Disorders	180
Introduction	180
Muscle disorders	180
Biomarkers of muscle fatigue during exercise	180
Biomarkers of mitochondrial content in skeletal muscle	180
Idiopathic inflammatory myopathies	181
Rheumatoid arthritis	181
Assays for biomarkers of RA	182
Biomarkers for personalizing therapy of rheumatoid arthritis	182
Circulating cytokines in RA	183
Epigenetic biomarkers of rheumatoid arthritis	183
miRNA biomarkers in RA	183
Serum CRP in RA	184
Biomarkers of spondylarthritis	184
Biomarkers of axial spondyloarthritis	185
Biomarkers of psoriatic arthritis	185
Osteoarthritis	185
Molecular pathophysiology of OA	186
Biomarkers of osteoarthritis	186
Assays for biomarkers of OA	187
Biomarkers of OA	187
Concluding remarks and future prospects of biomarkers of OA	188
Biomarkers of osteoporosis	188
Assays for detection of biomarkers of osteoporosis	188
Bone imaging with quantitative CT and MRI	189
Circulating miRNAs as biomarkers of osteoporosis	189
Dual x-ray absorptiometry	190
Utility of biomarkers of osteoporosis	190
Biomarkers of osteonecrosis	190
Osteonecrosis in Gaucher's disease	190
9. Biomarkers of Infectious Diseases	192
Introduction	192
Technologies for discovery of biomarkers of infection	192
Chemokines as biomarkers of infection	192
Endotoxin as biomarker of infection	192
Proteomics for discovering biomarkers of infections	192
Soluble urokinase plasminogen activator receptor	193
Sepsis	193
Biomarkers of sepsis	194
<i>Circulating CPS-1 as biomarkers of organ damage in sepsis</i>	<i>195</i>
<i>CoQ10 level reduction in septic shock</i>	<i>195</i>
<i>Multibiomarker-based outcome risk stratification of septic shock</i>	<i>196</i>
<i>Nitric oxide as a biomarker of sepsis</i>	<i>196</i>
<i>SuPAR as a biomarker of sepsis</i>	<i>196</i>
Systemic inflammatory response syndrome	197
Tuberculosis	197
Conventional diagnosis of tuberculosis	198
Molecular diagnostics for tuberculosis	198
Biomarkers for tuberculosis	198
Biomarkers of pulmonary tuberculosis in the breath	199
Biomarkers of viral infections	199
Viral hepatitis	199
Biomarkers of SARS	201
Biomarkers of HIV	202
Biomarkers in parasitic infections	203
Role of biomarkers in malaria	203
Identification of biomarkers in Schistosomiasis infections	203
Diagnostic & therapeutic applications of biomarkers of infections	204
Biomarkers to discriminate bacterial from nonbacterial respiratory infections	204
Procalcitonin as a guide to antibiotic therapy in infections	204
10. Biomarkers of Genetic Disorders	206
Introduction	206
Biomarkers of Down's syndrome	206
Biomarkers of muscular dystrophy	206
Biomarkers of phenylketonuria	207
Genetic biomarkers of psoriasis	207
Biomarkers of lysosomal storage disorders	208
Biomarkers of Niemann-Pick disease	208
<i>Bile acids as biomarkers for the early diagnosis of NPD</i>	<i>208</i>

<i>Cholesterol oxidation products as biomarkers of NPD</i>	208
Biomarkers of mucopolysaccharidoses	209
<i>Proteomic technologies for biomarkers of MPS</i>	209
<i>Glycan-based biomarkers for MPS</i>	210
<i>Biomarkers of LSD</i>	210
<i>Prenatal diagnosis of LSD</i>	210
Biomarkers of Fabry's disease	211
11. Biomarkers of Aging	212
Introduction	212
Biomarkers of biological age.....	213
Gene variants as determinants of biological age.....	214
Gene expression profiles for calculating transcriptomic age	214
Biomarkers of healthy aging	214
Biomarkers of longevity	215
Effect of calorie restriction on biomarkers of longevity	215
Healthy aging index	215
Low serum thyroid hormone level as biomarker of longevity	215
Biomarkers as predictors of mortality with aging	216
Genetic biomarkers of aging.....	216
Genetic signatures of longevity	216
Metabolomic biomarkers of aging	217
Mitochondrial mutations as biomarkers of aging	217
Oxidative biomarkers of aging	217
Molecular diagnostics and biomarkers of age-related diseases.....	218
Protein biomarkers of aging	218
Carbamylated proteins as biomarkers of aging	218
Proteomic biomarkers of muscle aging.....	219
Role of humanin in age-related diseases	219
Role of bioinformatics in search for biomarkers of aging	219
Aging biomarkers in a genetically homogeneous population	219
Telomere attrition as aging biomarker	220
12. Nutritional Biomarkers	222
Introduction	222
Biomarkers of Nutrition for Development project	222
Biomarkers in nutritional epidemiology	222
Biomarkers of nutritional status	223
Ferritin as biomarker of nutritional status.....	223
Folate biomarkers related to nutritional health status	224
Iodine as biomarker of nutritional status	224
Zinc as a biomarker of nutritional status	225
Biomarkers of branched chain amino acid status.....	225
Biomarkers of caloric restriction.....	225
Biomarkers of malnutrition.....	225
Maternal nutrition during early pregnancy causes epigenetic changes	226
Proteomic biomarkers and nutrition	226
Vitamin deficiency as biomarker of disease	226
Vitamin A biomarkers	226
Vitamin B12 deficiency	227
Vitamin D deficiency as a biomarker of disease.....	228
Role of biomarkers in the development of personalized nutrition	228
13. Biomarkers of Cancer.....	230
Introduction	230
The ideal biomarker for cancer	230
Biomarkers and hallmarks of cancer	231
Single vs multiple biomarkers of cancer	231
Types of cancer biomarkers	232
miRNAs as biomarkers in cancer	232
<i>Diagnostic value of miRNA in cancer</i>	234
Biomarkers of epigenetic gene silencing in cancer	234
<i>5-hydroxymethylcytosine as a biomarker of cancer</i>	235
Carcinoembryonic antigen.....	235
Circulating cancer biomarkers.....	235
<i>Circulating tumor cells as cancer biomarkers</i>	235
<i>Circulating nucleic acids as potential biomarkers of cancer</i>	236
<i>Circulating exosomes and microvesicles as biomarkers of cancer</i>	236
<i>Circulating miRNAs for cancer detection</i>	237
DNA repair biomarkers	237
HER3 as biomarker of cancer.....	237

Immunologic and inflammation biomarkers of cancer	237
Metastatic cancer biomarkers	238
Molecular diagnostic techniques for cancer	238
Technologies for detection of cancer biomarkers.....	240
Genomic technologies for cancer biomarkers	240
<i>Biomarkers of PTEN tumor suppressor gene status.....</i>	240
<i>Cold-PCR</i>	240
<i>ddPCR for detection of cancer biomarkers in cell free plasma DNA.....</i>	241
<i>Digital karyotyping for cancer biomarkers</i>	241
<i>Genome analysis at the molecular level</i>	241
<i>KRAS as a biomarker of cancer</i>	242
<i>LigAmp for detection of gene mutations in cancer</i>	242
<i>Mitochondrial DNA as a cancer biomarker.....</i>	242
<i>Next generation sequencing for detection of cancer biomarkers.....</i>	243
<i>Telomerase as a biomarker of cancer</i>	244
Tissue microarrays for study of cancer biomarkers	244
Molecular fingerprinting of cancer	245
Proteomic technologies for detecting biomarkers of cancer	245
2D PAGE	246
<i>Antibody-based detection of protein biomarkers</i>	246
<i>Aptamer-based molecular probes for cancer biomarker discovery.....</i>	247
<i>Biomarkers of protein-drug interactions in cancer</i>	247
<i>Cancer immunomics to identify autoantibody signatures</i>	248
<i>Desorption electrospray ionization for detection of cancer biomarkers.....</i>	248
<i>Detection of circulating nucleosomes in serum of cancer patients.....</i>	248
<i>Detection of tumor biomarkers with ProteinChip technology</i>	249
<i>Glycoprotein biomarkers of cancer</i>	249
<i>HER-2/neu oncoprotein as biomarkers for cancer</i>	249
<i>Humoral proteomics</i>	250
<i>Laser capture microdissection.....</i>	250
<i>Membrane-type serine protease-1.....</i>	250
<i>Proteomic analysis of cancer cell mitochondria.....</i>	251
<i>Proteomic technologies for detection of autoimmune biomarkers</i>	251
SELDI-TOF MS	252
<i>Serum proteome analysis for early detection of cancer</i>	252
<i>Synthetic biomarker-based POC diagnostic for cancer.....</i>	252
<i>Triple-quadrupole MS for detection of mutant proteins.....</i>	252
<i>Targeted MS for validation of cancer biomarkers in plasma</i>	253
<i>Tissue proteomics for discovery of cancer biomarkers.....</i>	253
<i>VeraTag system for cancer biomarkers</i>	253
Metabolomic biomarkers of cancer	253
<i>Magnetic resonance for detecting metabolomics biomarkers of cancer</i>	254
<i>Choline phospholipid biomarkers of cancer</i>	254
<i>Hypoxia-inducible factor-1</i>	254
<i>Detection of drug resistance in cancer by metabolic profiling</i>	255
<i>Plasma free amino acids profiling in cancer</i>	255
<i>Urinary metabolomic biomarkers of cancer.....</i>	256
Epitomics for the early detection of cancer	256
Epigenetic biomarkers of cancer	256
<i>Detection of biomarkers of DNA methylation</i>	257
<i>Epigenomics Marker Machine for DNA methylation biomarkers.....</i>	258
<i>Histone deacetylase</i>	258
<i>MDScaTM microarray technology</i>	258
<i>Mucins as epigenetic biomarkers in epithelial cancers</i>	259
<i>PCR with bisulfite for detecting DNA methylation biomarkers in cancer</i>	259
<i>Detection of methylated DNA in serum and urine</i>	260
<i>Integrated platform for genetic and epigenetic analysis</i>	260
Nanobiotechnology for early detection of cancer to improve treatment	261
<i>Aptasensor for electrochemical detection of exosomes.....</i>	261
<i>Nanovesicles for detection of cancer biomarkers</i>	261
<i>Nanowire biosensors for detection of cancer biomarkers</i>	262
<i>NP-peptide complexes for detection of cancer biomarkers in urine.....</i>	263
Ultrasound radiation to enhance release of a tumor biomarker	263
In vivo imaging of cancer biomarkers	263
Computer tomography.....	263
<i>Optical systems for in vivo molecular imaging of cancer.....</i>	264
<i>Positron emission tomography</i>	264
<i>Imaging of tumor oxygenation and microvascular permeability by MRI</i>	264
<i>Xenon-enhanced MRI</i>	265
Kallikrein gene family and cancer biomarkers	265
Detection of CTCs as biomarkers of cancer	265

Applications of cancer biomarkers	266
Use of biomarkers for cancer classification	266
<i>Cancer classification using microarrays</i>	266
<i>Proteomic classification of cancer</i>	267
Use of biomarkers for early detection of cancer	267
Applications of biomarkers for cancer diagnosis	267
<i>Methylated DNA sequences as cancer biomarkers</i>	267
<i>MicroRNA expression profiling for diagnosis of human cancers</i>	268
<i>MUC4 as a diagnostic biomarker in cancer</i>	269
Applications of biomarkers for cancer diagnosis and therapy	269
<i>ARTS as a biomarker as well as a basis of anticancer drugs</i>	270
<i>Asparagine synthetase as biomarker for therapy with L-asparaginase</i>	271
<i>Peptide-based agents for targeting cancer biomarkers</i>	271
<i>PI3K mutations as a biomarker for use as a companion diagnostic</i>	271
Biomarkers for assessing efficacy of cancer therapy	272
<i>ERCC1-XPF expression as a biomarker of response to chemotherapy</i>	272
<i>P53 expression level as biomarker of efficacy of cancer gene therapy</i>	272
Biomarkers of angiogenesis for developing antiangiogenic therapy	272
<i>Biomarkers of response to antiangiogenic agents</i>	272
<i>Circulating endothelial cells as targets for antiangiogenic drugs</i>	273
<i>Imaging biomarkers for evaluation of antiangiogenic agents</i>	273
<i>Tumor endothelial biomarkers</i>	274
<i>VEGF signaling inhibitors as biomarkers</i>	274
<i>VEGF-PET imaging for analysis of angiogenic changes within a tumor</i>	274
Biomarkers of prognosis in cancer treatment	275
Biomarkers for monitoring cancer therapy	275
Biomarkers of drug resistance in cancer	275
<i>A systems approach to biomarkers of innate drug resistance</i>	276
<i>Epithelial membrane protein-1 as a biomarker of gefitinib resistance</i>	276
<i>Methylation biomarkers of drug resistance in cancer</i>	276
<i>STAT3 and resistance to cisplatin</i>	277
Biomarkers of radiation therapy for cancer	277
Role of biomarkers in drug development in oncology	277
Biomarker-based approval of an anticancer drug regardless of site	278
Biomarkers in plucked hair for assessing cancer therapy	279
Met receptors as targets for anticancer drugs	279
Molecular imaging of tumor as a guide to drug development	279
<i>Use of PET and SPECT to assess response to anticancer drugs</i>	280
<i>Use of MRI to assess response to anticancer drugs</i>	280
Role of biomarkers in phase I clinical trials of anticancer drugs	281
Safety biomarkers in oncology studies	281
Biomarkers according to organ/type of cancer	281
Bladder cancer biomarkers	282
<i>Detection of FGFR3 mutations in urine for diagnosis of bladder cancer</i>	282
<i>NMP22 BladderChek</i>	282
<i>Urinary telomerase as biomarker for detection of bladder cancer</i>	282
<i>Concluding remarks about biomarkers of urinary cancer</i>	282
Brain tumor biomarkers	283
<i>14-3-3zeta positive expression as a prognostic biomarker for GBM</i>	283
<i>ALDH1A3 as a biomarker of GBM</i>	284
<i>Biomarkers to predict response to EGFR inhibitors</i>	284
<i>Biomarkers for predicting recurrence of meningiomas</i>	284
<i>CD133 as biomarker of resistance to radiotherapy</i>	284
<i>Circulating microvesicles as biomarkers</i>	285
<i>CSF attractin as a biomarker of malignant astrocytoma</i>	285
<i>ELTD1 as a biomarker of gliomas</i>	285
<i>Methylation profiling of brain tumors</i>	285
<i>Metabolite biomarkers of brain tumors</i>	287
<i>miRNAs as biomarkers of brain tumors</i>	287
<i>MRI biomarker for response of brain tumor to therapy</i>	288
<i>Multigene predictor of outcome in GBM</i>	288
<i>Neuroimaging biomarkers combined with DNA microarray analysis</i>	288
<i>Proteomic analysis of CSF for identification of biomarkers for gliomas</i>	288
<i>Receptor protein tyrosine phosphatase β as biomarker of gliomas</i>	289
<i>Serum protein fingerprinting</i>	289
<i>VEGF-R2 as biomarker of angiogenesis in brain tumors</i>	289
<i>Future prospects of biomarkers of malignant gliomas</i>	289
Bone tumor biomarkers	290
<i>Cytogenetics for the study of bone and soft tissue tumors</i>	290
<i>Biomarkers of Ewing's tumors</i>	290
<i>Role of biomarkers in the diagnosis of bone tumors</i>	290

Breast cancer biomarkers	291
Autoantibody biomarkers of breast cancer.....	292
Biomarkers of breast cancer in breath	293
Biomarkers for breast cancer in nipple aspiration fluid	293
Circulating tumor DNA as biomarker of breast cancer	293
Circulating exosomes as biomarkers of breast cancer	293
Flow cytometry for quantification of biomarker expression patterns.....	294
Plasma proteomics for biomarkers of breast cancer	294
Quantitative realtime PCR assays for biomarker validation	294
Cdk6 as a biomarker of breast cancer.....	295
Centromere protein-F.....	295
Carbonic anhydrase IX.....	296
COX-2 as a biomarker of breast cancer.....	296
G88 as a biomarker of progression of ER+ breast cancer	296
Glycomic biomarkers of breast cancer.....	296
HER-2/neu oncoprotein.....	297
High mobility group protein A2	298
Hypermethylated genes as biomarkers of metastatic breast cancer	298
Lipocalin 2 as biomarker of breast cancer progression	298
Long intervening non-coding RNAs.....	299
Mammaglobin.....	299
miRNA biomarkers of breast cancer.....	299
p27 expression as biomarker for survival after chemotherapy.....	300
Podocalyxin.....	301
Proneurotensin and Proenkephalin	301
Proliferating cell nuclear antigen	301
Protein kinase C as a predictive biomarker of metastatic breast cancer.....	301
Retinoblastoma tumor suppressor gene as a biomarker	302
Riboflavin carrier protein.....	302
Risk of invasive cancer after diagnosis of ductal carcinoma in situ	302
Serum CA 15-3 as biomarker of prognosis in advanced breast cancer.....	303
Stage-specific embryonic antigen-3.....	303
Suppressor of deltex protein.....	303
Tumor microenvironment as biomarker of metastasis in breast cancer.....	303
Type III TGF- β receptor as regulator of cancer progression	304
Diagnostic tests based on breast cancer genes	304
Prognostic role of breast cancer genes.....	305
Protein biomarkers for breast cancer prevention	306
Biomarkers to evaluate efficacy of chemoprevention	306
Biomarkers of response to chemotherapy of breast cancer	306
Biomarker-guided decisions for breast cancer therapy	307
Concluding remarks and future prospects of breast cancer biomarkers	307
Cervical cancer biomarkers	307
Gastrointestinal cancer biomarkers	308
Esophageal cancer biomarkers.....	309
Gastric cancer biomarkers.....	309
Colorectal cancer biomarkers.....	310
Head and neck cancer	316
Leukemia biomarkers	317
Chromosome translocations in leukemias.....	318
DNA methylation biomarkers in leukemia.....	318
Gene mutations as biomarkers in leukemia	319
Molecular diagnostic techniques for leukemia.....	319
Proteomic technologies for discovering biomarkers of leukemia.....	319
Biomarkers of chronic lymphocytic leukemia.....	320
Biomarkers of chronic myeloid leukemia	321
Biomarkers of drug resistance in leukemia	321
Biomarkers of myelodysplastic syndromes.....	321
Lymphoma biomarkers	321
Liver cancer biomarkers.....	322
Biomarkers indicating lower risk of HCC in coffee drinkers.....	323
Metabonomic profiles discriminate HCC from liver cirrhosis	323
Urinary biomarkers of HCC.....	323
Lung cancer biomarkers.....	323
Autoantibodies as biomarkers in lung cancer	325
Biomarkers associated with neuroendocrine differentiation in NSCLC.....	325
Biomarkers of chronic inflammation in lung cancer	326
Biomarkers for predicting sensitivity to chemotherapy in lung cancer	326
Biomarkers for prediction of sensitivity to EGFR inhibitors	327
CTCs as biomarkers of lung cancer.....	327
Genomic biomarkers of lung cancer.....	328

<i>Methylation biomarkers of lung cancer</i>	328
<i>miRNA biomarkers in lung cancer</i>	329
<i>Noninvasive detection of lung cancer using exhaled breath</i>	330
<i>Serum protein biomarkers of lung cancer</i>	330
<i>tNOX as biomarker of lung cancer</i>	331
<i>Tumor-derived DNA and RNA markers in blood</i>	331
<i>Volatile organic compounds in the exhaled breath</i>	332
Malignant pleural mesothelioma.....	332
Melanoma biomarkers.....	332
Nasopharyngeal carcinoma biomarkers.....	334
<i>Proteomic biomarkers of nasopharyngeal cancer</i>	335
<i>miRNA biomarkers of nasopharyngeal carcinoma</i>	335
Oral cancer biomarkers.....	336
Ovarian cancer biomarkers.....	336
<i>3D microfluidic platform to assess multiple ovarian cancer biomarkers</i>	337
<i>CA125 as biomarker of ovarian cancer</i>	337
<i>Epitomics approach for ovarian cancer biomarkers in serum</i>	338
<i>FGF18 as a biomarker in ovarian cancer</i>	338
<i>Gene expression studies in ovarian cancer</i>	338
<i>HE4 protein in urine as a biomarker for ovarian cancer</i>	339
<i>Hematogenous metastasis of ovarian cancer</i>	339
<i>HtrA1 as a biomarker of response to chemotherapy in ovarian cancer</i>	339
<i>Mutation of genes in ovarian cancer</i>	340
<i>Serum biomarkers of ovarian cancer prognosis</i>	340
<i>TIM-3 as a biomarker of ovarian cancer</i>	340
<i>Multiplex assays for biomarkers of ovarian cancer</i>	341
<i>Concluding remarks on biomarker-based tests of ovarian cancer</i>	341
Pancreatic cancer biomarkers.....	342
<i>Discovery and validation of pancreatic cancer biomarkers</i>	343
<i>Cancer stem cells as biomarkers of pancreatic cancer</i>	343
<i>Circulating exosomes as biomarkers of pancreatic cancer</i>	343
<i>Histone modifications used as biomarkers in pancreatic cancer</i>	343
<i>miRNA biomarkers of pancreatic cancer</i>	344
<i>Macrophage inhibitory cytokine-1 as biomarker of pancreatic cancer</i>	345
<i>Proteomic biomarkers of pancreatic cancer</i>	345
<i>Concluding remarks on biomarkers of pancreatic cancer</i>	345
Parathyroid cancer biomarkers.....	346
Peripheral nerve tumors.....	346
<i>Biomarkers of neurofibromatosis</i>	346
Prostate cancer.....	347
<i>Adipose tissue-derived biomarkers of obesity-related prostate cancer</i>	347
<i>B7-H3 as biomarker of prostate cancer</i>	348
<i>Cancer genetics-guided biomarker signatures of prostate cancer</i>	348
<i>Detection of prostate cancer biomarkers in urine</i>	348
<i>Detection of prostatic intraepithelial neoplasia</i>	349
<i>Epigenetic biomarkers of prostate cancer</i>	349
<i>Exosomes as biomarkers of prostate cancer</i>	350
<i>Gene expression analysis of prostate cancer</i>	350
<i>Genetic biomarkers of prostate cancer</i>	351
<i>Identification of prostate cancer mRNA biomarkers</i>	351
<i>Kallikreins as biomarkers of prostate cancer</i>	352
<i>LCM for diagnosis of prostate cancer</i>	352
<i>Microarray for diagnosis of prostate cancer</i>	353
<i>miRNA biomarkers of prostate cancer</i>	353
<i>Prostate cancer biomarkers in semen</i>	354
<i>PSA as biomarker of prostate cancer</i>	354
<i>ProPSA as biomarker of prostate cancer</i>	355
<i>Prostate Health Index</i>	355
<i>Prostasomes in blood as biomarker of prostate cancer</i>	355
<i>PSMA as biomarker of prostate cancer</i>	356
<i>Sarcosine as a metabolic biomarker of prostate cancer</i>	356
<i>Silenced CDH13 gene as a biomarker of cancer</i>	356
<i>Serum-protein fingerprinting</i>	356
<i>Concluding remarks on biomarkers of prostate cancer</i>	357
Renal cancer biomarkers.....	357
<i>Gene expression profile of RCC for biomarkers</i>	357
<i>miRNA biomarkers of renal cancer</i>	358
<i>Use of proteomics for detection of RCC biomarkers</i>	358
<i>Use of RCC biomarkers for prognosis and therapy</i>	358
Thyroid cancer biomarkers.....	359
<i>Detection of BRAF mutation</i>	359

<i>Gene expression biomarkers of thyroid cancer</i>	360
<i>miRNA biomarkers of thyroid cancer</i>	360
<i>Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer</i>	360
Role of the NCI in cancer biomarkers	361
Future prospects for cancer biomarkers	362
Cancer biomarker research at academic institutions.....	362
Future challenges in the discovery of cancer biomarkers.....	362
14. Biomarkers of Disorders of the Nervous System	364
Introduction	364
Discovery of biomarkers for neurological disorders	364
Antibodies as biomarkers in disorders of the nervous system.....	365
Biomarker identification in the CSF using proteomics.....	366
Biomarker identification in the CSF using lipidomics.....	366
Cerebral microdialysis for the study of biomarkers of cerebral metabolism.....	366
Brain imaging for detection of biomarkers.....	367
Data mining for biomarkers of neurological disorders.....	367
Detection of protein biomarkers of CNS disorders in the blood.....	368
Genomic technologies for study of biomarkers of neurological disorders.....	368
Biomarkers of neuroinflammation	368
Biomarkers of neural regeneration	369
Biomarkers of disruption of blood-brain barrier	369
Biomarkers of neurotoxicity	370
Glial fibrillary acidic protein as biomarker of neurotoxicity.....	370
Single-stranded DNA as a biomarker of neuronal apoptosis.....	371
Biomarkers of neurogenetic disorders	371
Charcot-Marie Tooth disease.....	371
Duchenne and Becker muscular dystrophy.....	372
Early-onset torsion dystonia.....	373
Fragile X syndrome.....	373
Genetic neurotransmitter disorders.....	374
Hereditary neuropathy with liability to pressure palsies.....	374
Hereditary metabolic storage disorders with neurologic manifestations.....	374
<i>Gaucher disease</i>	374
<i>Pompe's disease</i>	375
Mitochondrial disorders affecting the nervous system.....	375
Spinal muscular atrophy.....	375
<i>Biomarkers of SMA</i>	376
Biomarkers of the aging brain	376
Cellular biomarker of aging of the brain.....	376
CSF F2-isoprostanates as biomarker of aging brain.....	376
IL-6 as a biomarker of cognitive impairment with aging.....	377
MRI transverse relaxation rate alteration as biomarker of aging brain.....	377
Protein aggregation as a biomarker of aging brain.....	377
Telomere shortening as a biomarker of aging brain and dementia.....	377
Biomarkers of neurodegenerative disorders	378
Biomarkers of dementia	378
Biomarkers of vascular dementia.....	379
Biomarkers of Alzheimer's disease	379
The ideal biomarker for AD.....	381
Methods for determining biomarkers of AD.....	381
<i>Gene expression patterns in AD</i>	381
<i>Magnetic resonance spectroscopy in AD</i>	382
<i>MicroRNAs as biomarkers of neurodegenerative disorders</i>	382
<i>MRI for biomarkers of AD</i>	383
<i>Nanotechnology to measure Aβ-derived diffusible ligands</i>	384
<i>PET scanning for biomarkers of AD</i>	384
<i>Simultaneous measurement of several biomarkers for AD</i>	386
<i>Targeting of chemokine receptor as biomarker for brain imaging</i>	386
Biomarkers of AD in CSF.....	387
<i>CSF sulfatide as a biomarker for AD</i>	387
<i>CSF Reelin as biomarker of AD</i>	387
<i>Monitoring of synthesis and clearance rates of Aβ in the CSF</i>	387
<i>Protein biomarkers of AD in CSF</i>	388
<i>Tau proteins in CSF</i>	389
<i>Tests for the detection of Aβ in CSF</i>	389
<i>Tests combining CSF tau and Aβ</i>	390
Blood biomarkers of AD.....	391
<i>A serum protein-based algorithm for the detection of AD</i>	391
<i>Amyloid precursor protein</i>	391
<i>Detection of aggregated misfolded proteins in the blood</i>	391

<i>Lipid biomarkers for preclinical detection of AD</i>	392
<i>Lymphocyte Proliferation Test</i>	392
<i>Metabolomic biomarker profiling</i>	392
<i>Plasma protein biomarkers of AD</i>	392
<i>Protein kinase C in red blood cells</i>	393
Urine tests for AD.....	394
A biomarker-based skin test for AD.....	394
Salivary biomarkers of AD.....	394
Applications of biomarkers of AD.....	395
<i>Biomarker changes in autosomal dominantly inherited AD</i>	395
<i>Correlation of imaging biomarkers with CSF biomarkers of AD</i>	395
<i>Genetic tests for AD</i>	395
<i>Humanin as a biomarker as well as neuroprotective in AD</i>	396
<i>Plasma biomarkers of drug response in AD</i>	396
<i>PredictAD project</i>	397
<i>TOMM40 gene and risk of AD</i>	397
<i>Use of biomarkers to predict AD in patients with MCI</i>	397
Concluding remarks about biomarkers for AD and future prospects.....	398
Biomarkers of Parkinson's disease	399
Autoantibodies as biomarkers of PD.....	400
Biomarkers of PD based on gene expression in blood.....	400
Cardiac denervation as a biomarker of PD.....	400
Caffeine levels in blood.....	401
Genetic biomarkers of PD.....	401
Imaging biomarkers of PD.....	402
Metabolic brain networks as biomarkers.....	402
Metabonomic biomarker profile for diagnosis and monitoring of PD.....	403
Protein biomarkers of PD.....	403
<i>P11 protein as a biomarker of depression in PD</i>	403
Serum vitamin D as a biomarker of PD.....	404
Biomarkers of prodromal PD.....	404
Future needs for biomarkers of PD.....	404
Biomarkers of Huntington's disease	405
Genetic biomarker of HD progression.....	406
Quantitative MRI measurement of brain atrophy as biomarker of HD.....	407
Metabolic networks as biomarkers of preclinical Huntington disease.....	407
Biomarkers of Wilson's disease	407
Biomarkers of amyotrophic lateral sclerosis	408
ALS biomarker detection in blood vs CSF.....	409
Biomarkers of neuroinflammation in ALS.....	409
Genetic biomarkers of ALS.....	409
Imaging biomarkers of ALS.....	410
Metabolomic biomarkers of ALS.....	410
Proteomic biomarkers of ALS.....	410
Ideal biomarker of ALS.....	411
Future of biomarkers of ALS.....	411
HIV-1-associated neurocognitive disorders	411
Biomarkers of dementia in HIV-1-infected patients.....	412
Biomarkers of autoimmune encephalitis	412
Biomarkers of prion diseases	412
14-3-3 protein and tTau/P-Tau ratio.....	412
Bioluminescence imaging as a surrogate biomarker of prion infectivity.....	413
miRNAs as biomarkers of prion-induced neurodegeneration.....	413
MRI biomarker of CJD.....	413
Prion protein detection by real-time quaking-induced conversion.....	414
Prions in the urine of patients with variant CJD.....	414
Biomarkers of multiple sclerosis	414
Antibodies in multiple sclerosis.....	416
<i>Antibodies to galactocerebroside</i>	416
<i>Antibodies to myelin oligodendrocyte glycoprotein</i>	416
Brain N-acetylaspartylglutamate as biomarker of cognitive function in MS.....	416
Brain imaging biomarkers of multiple sclerosis.....	417
<i>MRI biomarkers of multiple sclerosis</i>	417
<i>Molecular imaging</i>	417
Biomarkers of response to therapy of multiple sclerosis.....	418
<i>Biomarkers of response to of interferon β-1a</i>	418
<i>DNA motifs in the blood as biomarkers of response to treatment</i>	418
<i>Gene expression</i>	418
<i>Lymphocyte subsets as biomarkers of therapeutic response</i>	419
<i>Neurofilaments</i>	420
<i>Vitamin D as predictor of activity and progression of MS</i>	420

CSF biomarkers in multiple sclerosis.....	420
CSF Cystatin C as a biomarker of multiple sclerosis	420
Detecting autoantibodies in multiple sclerosis	420
<i>Switch-associated protein 70 antibodies in multiple sclerosis</i>	421
Gelsolin as a biomarker of multiple sclerosis.....	421
Matrix metalloproteinases as biomarkers in multiple sclerosis	421
Oligoclonal bands as biomarkers of MS	422
Serum proteomic pattern analysis in multiple sclerosis	422
T cells as biomarkers of multiple sclerosis	422
Concluding remarks and future perspective for biomarkers of multiple sclerosis.....	422
Biomarkers of cerebrovascular disorders.....	423
Biomarkers of stroke	423
<i>Etiological biomarkers of ischemic stroke</i>	425
<i>Brain natriuretic peptide as a biomarker for cardioembolic stroke</i>	426
<i>Brain lactate and N-acetylaspartate as biomarkers of stroke</i>	426
<i>CCL23 for prediction of stroke patient outcome</i>	426
<i>CRP as biomarker of risk of stroke</i>	426
<i>CSF biomarkers in acute stroke</i>	427
<i>Gene expression in blood following ischemic stroke</i>	427
<i>Glutathione S-Transferase-n</i>	427
<i>Intercellular adhesion molecule 1 as biomarker of ischemic stroke</i>	428
<i>Lp-PLA2 and CRP as biomarkers for stroke</i>	428
<i>Matrix metalloproteinase-9</i>	428
<i>miRNAs as biomarkers of stroke</i>	428
<i>Neuroserpin polymorphisms as a biomarker of stroke</i>	428
<i>NMDA receptors as biomarkers of excitotoxicity in stroke</i>	429
<i>Nucleosomes as biomarkers of stroke</i>	429
<i>PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke</i>	429
<i>Visinin-like protein 1</i>	430
<i>Biomarker panels for stroke</i>	430
<i>Future prospects for biomarkers of stroke</i>	430
Biomarkers of cerebral vasospasm	431
Biomarkers of intracerebral hemorrhage	431
Biomarkers of hypoxic brain damage.....	432
Biomarkers of ischemic brain damage.....	432
D-dimer as a biomarker of cerebral venous thrombosis.....	432
Biomarkers of traumatic brain injury	433
Technologies for identification of biomarkers of TBI	433
<i>Cerebral microdialysis for study of biomarkers of TBI</i>	433
<i>Proteomic technologies for biomarkers of TBI</i>	434
<i>Systems biology approach for discovery of biomarkers of TBI</i>	435
Biomarkers of TBI	435
<i>Aβ as a biomarker of TBI</i>	436
<i>CCL11 as a biomarker of chronic traumatic encephalopathy</i>	436
<i>Diffusion tensor imaging in TBI</i>	436
<i>Glial fibrillary acidic protein as biomarker of TBI</i>	436
<i>Hyperphosphorylated axonal neurofilament protein</i>	437
<i>IL-6 and nerve growth factor as biomarkers of TBI</i>	437
<i>Myelin basic protein</i>	437
<i>Neural exosome cargo</i>	437
<i>Neurofilament heavy chain</i>	437
<i>Serum S100β as biomarker of TBI</i>	438
<i>SNTF as a biomarker for predicting cognitive decline after mild TBI</i>	438
<i>Tau as biomarker of TBI</i>	439
<i>Ubiquitin C-terminal Hydrolase-L1</i>	439
Biomarkers of inflicted TBI in infants	440
Biomarkers of concussion.....	440
Clinical applications of biomarkers of TBI	440
Biomarkers of CNS infections.....	441
Biomarkers of bacterial meningitis	441
Biomarkers of viral infections of CNS.....	442
<i>Biomarkers of CNS HIV infection</i>	442
<i>CSF kynurenic acid level as a biomarker of tick-borne encephalitis</i>	442
<i>Serum uric acid levels as biomarker of acute CNS viral infections</i>	442
Biomarkers of epilepsy	443
Biochemical markers of epilepsy	443
Biomarkers of temporal lobe epilepsy	444
Biomarkers of drug-resistant epilepsy.....	444
Genetic epilepsies	444
Electrophysiological biomarkers of epilepsy	444
Imaging biomarkers of epilepsy	445

Protein biomarkers of inflammation in epilepsy	445
Biomarkers of normal pressure hydrocephalus	445
Biomarkers of pseudotumor cerebri.....	446
Biomarkers of retinal disorders	446
Biomarkers of age-related macular degeneration	446
Biomarkers of sleep disorders	447
Biomarker of excessive daytime sleepiness	447
Biomarkers of obstructive sleep apnea.....	448
Biomarkers of restless legs syndrome.....	448
Biomarkers of pain.....	449
Biomarkers of disorders with musculoskeletal pain	449
Biomarkers of neuropathic pain	449
Brain insular glutamate as biomarker of fibromyalgia	450
Biomarkers of visceral pain	450
Biomarkers of migraine.....	450
Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome	451
Biomarkers of psychiatric disorders.....	452
Anorexia nervosa	452
Attention-deficit hyperactivity disorder	452
Biomarkers of autism	453
<i>Epigenetics of ASD.....</i>	<i>453</i>
<i>Gastrointestinal microbiota disturbances and ASD.....</i>	<i>453</i>
<i>Genetic factors in ASD.....</i>	<i>454</i>
<i>Immune biomarkers of ASD</i>	<i>454</i>
<i>Metabolic disturbances in autism.....</i>	<i>454</i>
<i>Neurophysiological biomarkers</i>	<i>455</i>
<i>Role of oxidative stress in autism.....</i>	<i>455</i>
<i>Test for ASD based on a 55-gene expression panel</i>	<i>455</i>
<i>Umbilical cord biomarkers.....</i>	<i>456</i>
Biomarkers of bipolar disorder	456
Biomarkers of depression.....	456
<i>Biochemical biomarkers of depression</i>	<i>458</i>
<i>Biomarkers and response to antidepressant treatment</i>	<i>458</i>
<i>Cingulate cortex activity and response to antidepressants.....</i>	<i>459</i>
<i>Genetic biomarkers of response to antidepressants</i>	<i>459</i>
<i>Inflammatory biomarkers of depression and psychosis</i>	<i>459</i>
<i>P11 as a biomarker of depression</i>	<i>460</i>
<i>Panels of blood-based biomarkers for diagnosis of MDD.....</i>	<i>460</i>
<i>Plasma metabolomics for diagnosis of MDD.....</i>	<i>460</i>
<i>Post-partum depression.....</i>	<i>460</i>
Biomarkers of posttraumatic stress disorder	461
Biomarkers of psychosis	462
Biomarkers of schizophrenia.....	462
<i>Biomarkers of abnormalities of visual information processing</i>	<i>463</i>
<i>Genetic biomarkers of schizophrenia</i>	<i>463</i>
<i>Gene expression analysis of blood for biomarkers of schizophrenia.....</i>	<i>463</i>
<i>Metabolic biomarkers of schizophrenia.....</i>	<i>464</i>
<i>Proteomic studies for biomarkers of schizophrenia</i>	<i>464</i>
Biomarkers of suicide	464
15. Biomarkers of Cardiovascular Disorders	466
Epidemiology of cardiovascular disease.....	466
Biomarkers of cardiovascular diseases	466
Biomarkers of acute myocardial infarction	468
Genetic biomarkers of cardiovascular disorders.....	468
Methods for identification of cardiovascular biomarkers	470
Application of proteomics for biomarkers of cardiovascular disease	470
<i>Targeted MS-based pipeline approach</i>	<i>470</i>
<i>Cardiovascular disease biomarker panel.....</i>	<i>471</i>
Detection of biomarkers of myocardial infarction in saliva by a nanobiochip.....	471
Metabolomic technologies for biomarkers of myocardial ischemia	471
Imaging biomarkers of cardiovascular disease	471
<i>Annexin A5 as an imaging biomarker of cardiovascular disease.....</i>	<i>472</i>
<i>Cardiovascular MRI</i>	<i>472</i>
<i>Cardiovascular hybrid imaging.....</i>	<i>472</i>
<i>Myocardial perfusion imaging</i>	<i>472</i>
Implantable magnetic biosensors for detecting cardiac biomarkers.....	473
Applications of biomarkers of cardiovascular disease.....	473
Biomarkers for ischemic heart disease and myocardial infarction	473
<i>Troponin</i>	<i>474</i>
<i>Natriuretic peptide</i>	<i>475</i>

<i>Copeptin</i>	476
<i>Creatine kinase muscle brain</i>	477
<i>miRNAs as biomarkers of acute coronary syndrome</i>	477
<i>Myoglobin</i>	477
<i>Fatty acid binding protein</i>	477
<i>Growth Differentiation Factor-15</i>	478
<i>High density lipoprotein 2</i>	478
<i>Cripto-1 as a biomarker of myocardial infarction</i>	478
<i>Cataract as a biomarker of ischemic heart disease</i>	478
<i>Plasma CD93 as a biomarker for coronary artery disease</i>	479
<i>Plasma fetuin-A levels and the risk of myocardial infarction</i>	479
<i>YKL-40 as an inflammatory biomarker in ischemic heart disease</i>	479
Biomarkers of cardiomyopathy	479
<i>miRNA biomarkers of peripartum cardiomyopathy</i>	479
<i>Takotsubo cardiomyopathy</i>	480
<i>Troponin T levels in hypertrophic cardiomyopathy</i>	480
Biomarkers of heart failure.....	480
<i>Annexin A5 for prognosis of heart failure</i>	480
<i>Angiogenesis biomarkers</i>	481
<i>β-2a protein as a biomarker of heart failure</i>	481
<i>Desmin</i>	481
<i>Galectin-3 as biomarker of acute heart failure</i>	481
<i>G protein-coupled receptor kinase-2 as biomarker of CHF</i>	482
<i>KIF6 gene as biomarker of heart failure</i>	482
<i>Metabolic biomarkers of heart failure</i>	483
<i>miRNA biomarkers of heart failure</i>	483
<i>Natriuretic peptide as biomarker of heart failure</i>	483
<i>Oxidative stress as biomarker of heart failure</i>	484
<i>Future prospects for biomarkers of heart failure</i>	484
Biomarkers for atherosclerosis.....	484
<i>9p21-3 locus and coronary atherosclerosis</i>	484
<i>Adipocyte enhancer-binding protein 1</i>	485
<i>Gene signatures on leucocytes as biomarkers of atherosclerosis</i>	485
<i>Ghrelin as a biomarker of atherosclerosis</i>	486
<i>Imaging biomarkers of hypercholesterolemia/atherosclerosis</i>	486
<i>Inflammatory biomarkers of atherosclerosis</i>	486
<i>Lipid-modified proteins as biomarkers of atherosclerosis</i>	486
<i>Lp-PLA2 as biomarker of atherosclerotic heart disease</i>	486
<i>Metabolomic profile in hypercholesterolemia</i>	487
<i>Nitric oxide impairment and atherosclerosis</i>	487
<i>Oxygen free radicals as biomarkers of atherosclerosis</i>	487
<i>Proteomic profiles of serum inflammatory biomarkers of atherosclerosis</i>	487
Biomarkers of coronary heart disease.....	488
<i>Apolipoproteins as risk factors for coronary heart disease</i>	488
<i>CRP as biomarker of risk for coronary heart disease</i>	488
<i>High level of blood ceramides as a biomarker of CHD</i>	489
<i>Impairment of EPCs by oxidative stress as a biomarker of disease</i>	489
<i>Role of TNF in acute coronary syndromes</i>	490
<i>Serum parathyroid hormone as biomarker of CHD</i>	490
<i>Serum stem cell factor as a biomarker of CHD</i>	490
<i>VILCAD biomarker score for prediction of long-term mortality in CHD</i>	490
Biomarkers for pulmonary arterial hypertension.....	491
Biomarkers of abdominal aortic aneurysm.....	491
Biomarkers of thrombotic disorders	493
Biomarkers of arterial thromboembolism.....	493
<i>Nanoparticles as synthetic biomarkers of thrombus formation</i>	493
Biomarkers of venous thromboembolism.....	493
<i>BNP and cTnT as biomarkers of outcome in pulmonary embolism</i>	493
<i>D-dimer as biomarker of venous thromboembolism</i>	494
<i>Molecular biomarkers of venous thromboembolism</i>	494
Genetic biomarkers for cardiovascular disease.....	494
<i>Biomarkers of inherited cardiomyopathies</i>	494
<i>Gene mutations in pulmonary arterial hypertension</i>	494
<i>Gene variant as a risk factor for sudden cardiac death</i>	495
<i>Genetic biomarkers of early onset myocardial infarction</i>	495
<i>Genetic biomarkers of atherosclerosis</i>	495
<i>IL-1 gene polymorphism as biomarker of cardiovascular disease</i>	496
<i>IL-6R signaling pathway and coronary heart disease</i>	496
<i>Kallikrein gene mutations in cardiovascular disease</i>	496
<i>Kallikrein gene and essential hypertension</i>	497
<i>Mutations in the low density lipoprotein receptor gene</i>	497

<i>Mutations within several genes that code for ion channel</i>	497
<i>Polymorphisms of the eNOS gene and angina pectoris</i>	498
<i>Lipoprotein (a) genetics</i>	498
<i>Polymorphisms in the apolipoprotein C gene</i>	498
<i>Polymorphisms in the apolipoprotein E gene</i>	499
<i>Polymorphism in the angiotensinogen gene</i>	499
Multiple biomarkers for prediction of death from cardiovascular disease.....	499
Role of biomarkers in the management of cardiovascular disease	500
Biomarkers in the diagnosis/prognosis of myocardial infarction.....	500
Biomarkers for prevention of cardiovascular disease.....	500
C reactive protein as biomarker of response to statin therapy.....	502
HSP72 and eNOS as biomarkers of cardioprotective effect of HBO.....	502
Multimarker panel for prognosis in chronic heart failure	503
Molecular signature analysis in management of cardiovascular diseases	503
Presage ST2 Assay.....	503
Role of circulating biomarkers and mediators of cardiovascular dysfunction.....	504
Use of protein biomarkers for monitoring acute coronary syndromes.....	504
Use of biomarkers for prognosis of recurrent atrial fibrillation	504
Use of multiple biomarkers for monitoring of cardiovascular disease.....	505
Use of biomarkers in the management of peripheral arterial disease	505
Use of biomarkers in the management of hypertension.....	505
Systems approach to cardiovascular biomarker research	506
16. Biomarkers of Pulmonary Diseases	508
Introduction	508
Association of biomarkers of inflammation with lung function in the elderly.....	508
Biomarkers of oxidative stress in lung diseases.....	509
Biomarkers of community-acquired pneumonia.....	509
Biomarkers of acute lung injury and respiratory distress syndrome	509
<i>Cytokine/chemokine biomarkers of SARS</i>	509
<i>Plasma biomarkers related to inflammation</i>	510
<i>Urinary NO as biomarker</i>	510
Biomarkers of interstitial lung disease	510
<i>Pulmonary surfactant proteins as biomarkers for lung diseases</i>	510
<i>Serum KL-6 as biomarker of interstitial lung disease</i>	511
Biomarkers of chronic obstructive pulmonary disease.....	511
<i>Alpha1-antitrypsin gene polymorphisms predisposing to emphysema</i>	511
<i>Biomarkers of extracellular matrix turnover in COPD</i>	512
<i>Biomarkers of lung failure in COPD</i>	512
<i>BNP as a biomarker of chronic pulmonary disease</i>	512
<i>Chromagranin A (CgA) as biomarker of airway obstruction in smokers</i>	513
<i>C-reactive protein as a biomarker of COPD</i>	513
<i>Gene expression profile in peripheral blood of patients with COPD</i>	513
<i>Hyperuricemia as a biomarker of early mortality in COPD</i>	513
<i>Increased expression of PIGF as a biomarker of COPD</i>	513
Biomarkers of asthma	514
<i>Biomarker for rhinovirus-induced asthma exacerbation</i>	514
<i>Biomarkers for predicting response to corticosteroid therapy</i>	514
<i>Comparison of biomarkers of asthma and COPD</i>	514
<i>Cytokines as biomarkers of asthma severity</i>	515
<i>Exhaled NO as a biomarker of asthma</i>	515
<i>Endothelin-1 in exhaled breath as biomarker of asthma</i>	516
<i>IgE as guide to dosing of omalizumab for asthma</i>	516
<i>Periostin as a biomarker for treatment of asthma with lebrikizumab</i>	516
Biomarkers of cystic fibrosis.....	517
17. Biomarkers in Gynecology and Obstetrics	518
Introduction	518
Biomarkers of menopause	518
Biomarkers of premenstrual dysphoric disorder	518
Biomarkers of endometriosis	519
Biomarkers for preeclampsia	519
Pathogenesis of preeclampsia.....	519
Metabolomic biomarkers in urine in preeclampsia.....	520
Protein biomarker of preeclampsia in urine.....	520
Protein biomarkers of preeclampsia in CSF.....	521
Protein HtrA1 as a biomarker for preeclampsia	521
Placental growth factor as a biomarker for preeclampsia	522
sFlt1 and soluble endoglin as biomarkers of preeclampsia	522
RNA biomarkers.....	522
Genes associated with preeclampsia.....	523

Biomarkers of premature birth	523
Proteomic biomarkers of premature birth	523
Biomarkers of oxidative stress in complicated pregnancies.....	524
Fetal biomarkers in maternal blood	524
Metabolic biomarkers of prenatal disorders in the mother.....	525
18. Biomarkers & Personalized Medicine	526
Introduction	526
Pharmacogenetics	526
Biomarkers and pharmacogenetics	527
Pharmacogenomics.....	528
Pharmacoproteomics	529
Single cell proteomics for personalized medicine	529
Role of biomarkers in development of personalized drugs.....	530
Metabolomic biomarker-based drug discovery	530
Use of biomarkers for developing MAb therapy in oncology	530
Biomarker tests for molecularly targeted therapies.....	531
Biobanking, biomarkers and personalized medicine in EU	532
Bioinformatics to sort biomarker data for personalized medicine	533
Biomarkers for monitoring response to therapy	534
Drug rescue by biomarker-based personalized medicine	534
Future role of biomarkers in personalized medicine	535
19. Biomarkers and Regulatory issues.....	536
Introduction	536
Biomarker validation	536
FDA criteria for a valid biomarker.....	536
FDA letter of support for biomarkers	538
Role of NIST in validation of cancer biomarkers	539
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays	539
National Biomarker Development Alliance	539
FDA perspective of biomarkers in clinical trials	540
FDA and predictive medicine.....	541
Biomarkers and FDA's Voluntary Genomic Data Submission	542
Role of imaging biomarkers in approval of drugs.....	542
Regulatory oversight of biomarker tests for targeted therapies	543
FDA and biomarkers	543
FDA consortium linking genetic biomarkers to serious adverse events	543
Oncology Biomarker Qualification Initiative	544
Critical Path Initiative	544
Predictive Safety Testing Consortium.....	546
The 21st Century Cures Act and biomarkers	546
From validated biomarker assay to a clinical laboratory diagnostic	547
Fast Path programs	548
Regulatory challenges in the biomarker field	548
FDA requirements of biomarkers and companion diagnostics	549
20. References.....	550
Tables	
Table 1-1: Historical landmarks in discovery and development of biomarkers	29
Table 1-2: Classification of biomarkers	29
Table 1-3: Terminology of clinically relevant biomarkers of disease	31
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors	41
Table 1-5: Comparison of various types of biomarkers	41
Table 1-6: Various "omics" technologies for discovery of biomarkers	43
Table 1-7: Role of biomarkers in translational medicine	44
Table 2-1: Classification of methods of gene expression analysis	47
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers	74
Table 2-3: Companies involved in developing molecular imaging	84
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers	108
Table 4-1: Companies using metabolomics for drug discovery	122
Table 4-2: Biomarker-based drug development at major pharmaceutical companies	123
Table 4-3: Causes of failures in clinical trials and their reduction by use of biomarkers	126
Table 5-1: Metabolic biomarkers of inflammatory diseases.....	140
Table 5-2: Oxidized phospholipids as biomarkers of various diseases	141
Table 5-3: Examples of biomarkers common to multiple diseases	155
Table 5-4: Examples of use of biomarkers in animal health	157
Table 6-1: Biomarkers of diabetes mellitus	161
Table 7-1: Biomarkers of Sjögren syndrome	177

Table 8-1: miRNAs deregulated in rheumatoid arthritic tissues	183
Table 8-2: Classification of inflammatory biomarkers in osteoarthritis.....	186
Table 9-1: Biomarkers of sepsis.....	195
Table 11-1: Biomarkers of aging.....	212
Table 12-1: Nutritional biomarkers.....	223
Table 13-1: Desirable characteristics of biomarkers for cancer	230
Table 13-2: Types of cancer biomarkers	232
Table 13-3: A classification of molecular diagnostic methods in cancer	239
Table 13-4: Cancer biomarkers used for diagnosis and therapy	269
Table 13-5: Novel biomarkers of prognosis in cancer treatment.....	275
Table 13-6: Biomarkers of brain tumors	283
Table 13-7: Biomarkers of breast cancer	291
Table 13-8: miRNA associated with breast cancer	300
Table 13-9: Biomarkers of colorectal cancer.....	310
Table 13-10: Biomarkers of lung cancer	324
Table 13-11: Classification of biomarkers of melanoma	333
Table 13-12: Biomarkers of nasopharyngeal carcinoma and potential applications	334
Table 13-13: Biomarkers of ovarian cancer	336
Table 13-14: Classification of biomarkers of pancreatic cancer	342
Table 13-15: Biomarkers of prostate cancer.....	347
Table 14-1: Biomarkers of cerebral metabolism	366
Table 14-2: Classification of biomarkers of Alzheimer disease in blood and CSF	379
Table 14-3: Characteristics of an ideal biomarker for Alzheimer disease	381
Table 14-4: miRNA expression in neurodegenerative diseases.....	382
Table 14-5: Biomarkers of Parkinson disease	399
Table 14-6: Biomarkers of Huntington disease	406
Table 14-7: Classification of biomarkers of amyotrophic lateral sclerosis.....	408
Table 14-8: Biomarkers of multiple sclerosis	415
Table 14-9: Gene expression as biomarker of response to interferon- β in multiple sclerosis	419
Table 14-10: Biomarkers of stroke.....	424
Table 14-11: Etiological blood biomarkers of ischemic strokes due to large artery atherosclerosis.....	425
Table 14-12: Biomarkers of traumatic brain injury	435
Table 14-13: Biomarkers of epilepsy	443
Table 14-14: Biomarkers of autism spectrum disorder.....	453
Table 14-15: Biomarkers of response to antidepressant treatment.....	458
Table 14-16: Biomarkers of posttraumatic stress disorder.....	461
Table 15-1: Classification of biomarkers for cardiovascular diseases.....	467
Table 15-2: Genes that cause cardiovascular diseases.....	469
Table 15-3: Biomarkers of abdominal aortic aneurysm	492
Table 15-4: Biomarkers for cardiovascular disease risk prediction	500
Table 16-1: Biomarkers of pulmonary diseases.....	508
Table 18-1: Pharmacogenetic vs. pharmacogenomic studies	527
Table 18-2: Applications of pharmacoproteomic biomarkers in personalized medicine.....	529
Table 19-1: Issued letters of support for biomarkers by the FDA.....	538
Table 19-2: Drugs requiring biomarker/companion diagnostic information in the label.....	549

Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare	44
Figure 1-2: Role of biomarkers in monitoring of diseases	45
Figure 2-1: The central role of spectrometry in proteomics	56
Figure 2-2: Selected reaction monitoring workflow for verification of biomarkers	70
Figure 4-1: Role of biomarkers in drug discovery and development process	112
Figure 4-2: Onion-peel model of biomarker development.....	127
Figure 5-1: Diseases associated with myositis autoantibodies.....	156
Figure 6-1: Plasma lipids in metabolic syndrome.....	167
Figure 8-1: β -CrossLaps bone resorption biomarker assay	189
Figure 13-1: Role of proteomics in the discovery of cancer biomarkers	246
Figure 13-2: Nanovesicles for detection of cancer biomarkers	262
Figure 13-3: Nanowire biosensor for cancer diagnosis	262
Figure 13-4: Cancer biomarker development and validation	362
Figure 14-1: Discovery and application of biomarkers in neurological diseases	364
Figure 14-2: MRI in Creutzfeld-Jakob disease.....	414
Figure 14-3: A scheme of pathogenesis of MDD with relevant biomarkers	458
Figure 15-1: Biomarkers of acute myocardial infarction related to pathophysiology	468
Figure 18-1: Role of pharmacogenetic biomarkers in personalized medicine.....	528
Figure 18-2: Workflow for developing metabolomics-based biomarkers for personalized treatment	530
Figure 18-3: Impact of biomarkers on personalized medicine	535
Figure 19-1: Stages and timelines of biomarker discovery, development and marketing	536
Figure 19-2: Biomarker qualification pilot process at the FDA.....	538
Figure 19-3: From a validated biomarker assay to a clinical laboratory diagnostic.....	547